louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06005454: The Impact of Fish Oil Supplementation on the Outcome of Children with Pneumonia I
Official title: The Impact of Fish Oil Supplementation on the Outcome of Children with Pneumonia in the Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumonia
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-08-22
Enrollment: 122
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Controlled Trial
Primary purpose: PREVENTION

Brief summary: The aim of study is to investigate the effect of enteral feeding of Omega-3 on the outcome of children with Pneumonia in PICU

Detailed description: Group A(cases) will be supplemented by omega-3 fatty acids for immediate post admission consecutive 7 days besides conventional treatment of pneumonia, in a dose of 350 mg twice daily for children less than 3 years and 450 mg twice daily for older children according to the standard treatment per the American Institute of Medicine of the National Academies guidelines for maximum dose for this age group. (Institute of Medicine of the National Academies,2016)

Side effects of omega-3 supplements are usually mild. They include unpleasant taste, bad breath, bad-smelling sweat, headache, and gastrointestinal symptoms such as heartburn, nausea, and diarrhea. (Office of Dietary Supplements ,2016)

Group B(controls) will be received enteral feeding without omega-3 fatty acid support.

Eligibility criteria: Inclusion Criteria

* All children patients with severe pneumonia admitted to PICU
* Both sexes
* Age: under 5 years
* Whose parents or caregivers approve for participation in the study

Exclusion Criteria

* Patients with chronic illnesses to exclude bias that could be emerged due to the chronic disease effect
* Whose parents or caregivers will not apply for participation in the study
* Patients who will be contraindicated for enteral feeding

Primary outcomes:
measure: Hospital length stay
timeFrame: Through study completion, an average of 1 yea
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Hoda Atef Abdelsattar Ibrahim
Study officials:
References:
Clinical trial NCT00013754: Pesticide Exposure Pathways for Farmworker Children
Official title: Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers (UW IRB 96-6567-C02, FENSKE, 6/15/00-6/14/01)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Poisoning
Keywords: pesticide
insecticide
organophosphate
exposure
child health
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS)
Sponsor class: NIH
Collaborators: name: Environmental Protection Agency (EPA)
First posted: 2001-03-30
Enrollment: 40
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: This project is aimed at better understanding how children living in agricultural environments are exposed to pesticides, and how such exposures can be prevented or reduced. The current project will characterize pesticide exposure pathways for children of farmworkers.

Detailed description: This project is aimed at better understanding how children living in agricultural environments are exposed to pesticides, and how such exposures can be prevented or reduced. Since 1991 our group has investigated pesticide expsoures among children of agricultural families in Washington state, focusing on exposure to organophosphate insecticides. We have demonstrated in these studies that the residential environments of agricultural families have higher pesticide residues than do other homes in this region. We have also found that children living in these residential environments have elevated levels of pesticide metabolites in their urine. We need to better understand how these children are being exposed in order to develop recomendations for exposure prevention or reduction. The current project will characterize pesticide exposure pathways for children of farmworkers. A complementary project is also underway by the UW-Child Health Center to develop and implement a community-wide intervention to reduce the transfer of pesticides from the workplace to the home (take home pathway).

Eligibility criteria: Each family recruited must include one child between the ages of 1-5.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Department of Environmental Health, University of Washington
state: Washington
Study officials:
References:
Clinical trial NCT03370354: Nursing Activity and Quality of Hospitalized Patients' Sleep
Official title: The Impact of Night Nursing Activity on the Quality of Hospitalized Patients' Sleep
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sleep Disorders, Circadian Rhythm
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
Collaborators: name: Professeur Pierre-Yves Marie, Cédric Baumann, Katie Galois, Romuald Zadra, Virginie Simon, Martine Lesny, Edith Dauchy, Saliha Sammari, Sylvie Klein
First posted: 2017-12-12
Enrollment: 328
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients hospitalized in a speciality medical units and who respond to the defined inclusion criteria. 5 units participate: nephrologye, neurology, cardiology, pneumology, endocrinology.

Brief summary: This study is to determine the impact of night shift nurse's activity on patients' sleeping patterns in medical services including individual, clinical and environmental factors. The patients will be questioned in order to create both a control group and a group with troubled sleeping patterns.

Detailed description: There are 5 speciality medical units involved. Patients must respond to the define inclusion criteria. Each patient will be asked if they agree to participate and if so will be asked to consent to participate.

Every day, nurses will give a questionnaire which will be completed by the patient to know if there were troubles sleeping patterns. If so, a second questionnaire will be completed by the patient.

Other data will be recorded such as personal informations, diagnostic, medical history, consumption habits and treatments.

The inclusion phase lasts 15 days maximum.

Eligibility criteria: Inclusion Criteria:

* Patient hospitalize in medical units
* In the unit since one night
* Patient over 18 years old
* Patient agree to participate

Exclusion Criteria:

* Patient who can't answer to the questionnaire for health reasons
* Patient who need a specific surveillance
* Patient recently operated

Primary outcomes:
measure: Presence of a sleeping disorder partially or totally related, according to patient's opinion, to night nursing activity
timeFrame: At the end of participation of patient- maximum at day 15 after inclusion
Secondary outcomes:
measure: Part of patients declaring disturbing elements related to night nursing activity
timeFrame: At day 15 after inclusion
measure: Disturbing elements related to night nursing activity
timeFrame: Every day during 15 days
measure: Individual and clinical disturbing elements
timeFrame: Every day during 15 days
measure: Average length of patients' sleep in patients with troubled sleeping during hospitalization
timeFrame: Every day during 15 days
measure: Sleep quality measured by Spiegel score
timeFrame: Every day during 15 days
Other outcomes:
Locations:
Study officials:
affiliation: CHRU Nancy France
name: Bridey Céline
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06403254: Evaluation of VSS Antibiotic Prophylaxis in Prosthetic Surgery (MRSA)
Official title: Seeking Bacterial Prevalence for Targeted Pre-Surgical Antibiotic Prophylaxis in Prosthetic Surgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Infection in Bone
Lead sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Sponsor class: OTHER
First posted: 2024-05-07
Enrollment: 700
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients, in a consecutive serie, based on criteria over indicated

Brief summary: based on international guide lines, antibiotic prophylaxis in Orthoaedic major surgery has to be done with a Cephalosporin 1st generation (e.g. Cefazolin 1 g 30' before surgery).

Since more than 10 years ago the investigators started evaluatinf infections in such a surgery, well demosntrating a level below 1% and, more important, a responsability of MRSA. considering Cephalosporin 1st generation useful but not determinat in such a surgery, investigators consider the use of a Glycopepide (Vancocyn 1 g in Very short. The primary outcome is to evaluate the validity of such proposal, performing a study of prevalence.

Detailed description: Patients enrolled in the study have to follow rhese steps:

T0: Clinical evaluation and Cephalosporin VSS prophylaxis, as usual T1: Surgery for TKA or THA T2: Post-operative --\> control and, if an infextion is supposed, Coltural examination and ABG T3: Post-op orthopedic control at 6 months, to evaluate any possible infection T4: Post-op clinical valuation at 12 months, with the same goal

Eligibility criteria: Inclusion Criteria:

Patiens male and female, old more than 40 years TKA or THA Surgeryntervento di chirurgia protesica ASAC II or even III, without any acute coexisting disease Informed consent -

Exclusion Criteria:Patients with infection before surgery Immunocompromise patient (e.g. Diabeties with glicate HB indicating a metabolic bad compensation) Patient with coagulation disorders Pregnancy Informed consent denied

-

Primary outcomes:
measure: Infections
timeFrame: 1 year after the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Istitutio Ortopedico Galeazzi Sede San Siro
state: Lumbardy
Study officials:
References:
Clinical trial NCT04736654: Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Disability Questionnaire
Official title: Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Disability Questionnaire
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Headache
Headache Disorders
Headache, Migraine
Headache, Tension
Headaches Chronic
Headaches Muscular
Keywords: Headache
Reliability
Validity
Cross-cultural adaptation
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2021-02-03
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population will consist of individuals with any type of headache.

Brief summary: The purpose of this study was to investigate cultural adaptation, reliability and validity of the Turkish version of the Headache Disability Questionnaire (HDQ).

Detailed description: When the outcome criteria for the physiotherapy of headache are considered in clinical studies and practice, parameters such as headache frequency, duration and severity are frequently used. Physiotherapists treat musculoskeletal dysfunction in various types of headache, including migraine, tension headache, and cervicogenic headache. The Headache Disability Questionnaire (HDQ), which was developed to measure the quality of life of a general population receiving physiotherapy and experiencing headache, evaluates the pain intensity, daily life activities, disruptions in work or school life, and the influence of the recreational activities of individuals. HDQ consists of 9 items and each item is rated between 0 and 10. Increasing the score indicates the seriousness of the impact. The study is planned with 45 individuals with gluteal tendinopathy. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in HDQ, Migraine Disability Assessment Questionnaire, Headache Impact Test-6 and Short Form-36.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with any type of headache,
* Have a chronic headache.

Exclusion Criteria:

* Having a cognitive and neurological disorder.

Primary outcomes:
measure: Headache Disability Questionnaire (HDQ)
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Halime ARIKAN
state: None Selected
Study officials:
References:
Clinical trial NCT06470854: Effect of Nebulized Dexmedetomidine on Post-dural Puncture Headache
Official title: Nebulized Dexmedetomidine for Post-dural Puncture Headache: A Comparative Case-Control Study Versus Bilateral Greater Occipital Nerve Block
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-Dural Puncture Headache
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-06-24
Enrollment: 50
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dural puncture during neuroaxial procedures is the most frequent major complication that causes the development of post-dural puncture headache (PDPH) in 16%-86% of cases. PDPH could be defined as severe positional headache that usually presents during the first 72-h following accidental dural puncture.

Dexmedetomidine (DXM) is a potent and highly selective α2-adrenergic agonist that was approved for ICU and procedural sedation in adults. Additionally, DXM has pleiotropic effects for its sympatholytic, amnestic, and analgesic properties. Regarding routes of administrations, DXM allows high flexibility and can be administered through intravenous (IV), intramuscular, buccal, intranasal and inhalational routes.

Nebulized DXM at 1 µg/kg is a favorable alternative to the intravenous route in short duration surgeries because it attenuates heart rate response to laryngoscopy. However, the effects of nebulized DXM on blood pressure are controversial.

it was assured that it has a role in reduction of the intraoperative anesthetic requirements and analgesic consumption.

The prophylactic and management strategies for PDPH are heterogeneous because of the absence of clear guidelines and protocols for the management of PDPH. However, the general plan for PDPH management consists of conservative treatment and if failed invasive procedures such as blood patch were applied.


Eligibility criteria: Inclusion Criteria:

* Women had CS under spinal anesthesia;
* Women started to complain of PDPH;
* Women were free of exclusion criteria.

Exclusion Criteria:

* Women had prior history of PDPH or headache for any cause;
* Women had essential hypertension;
* Women with previous history of habitual hypotension or accidental syncope secondary to postural hypotension;
* Women with tempromandibular disorders;
* Women who refused to participate in the study were excluded.

Primary outcomes:
measure: The extent of reduction of consumed analgesia
timeFrame: 5 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El Gharbyia
Study officials:
References:
Clinical trial NCT01250054: Comparison of Two Multifocal Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Presbyopia
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2010-11-30
Enrollment: 17
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare two multifocal contact lenses in presbyopic wearers.


Eligibility criteria: Inclusion Criteria:

* At least 35 years of age.
* Sign written Informed Consent
* Spectacle add of +0.50 to +2.50D.
* Best corrected visual acuity of at least 20.30 in both eyes.
* Currently wearing soft contact lenses at least 5 days per week.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Eye injury or surgery within twelve weeks of enrollment.
* Currently enrolled in any clinical trial.
* Astigmatism \> 1.00D.
* Strabismus/amblyopia.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Overall Vision
timeFrame: One week of wear
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00336154: Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
Official title: Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Epidermolysis Bullosa
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2006-06-13
Enrollment: 0
Sex: ALL
Minimum age (years): 13
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Detailed description: Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Eligibility criteria: Inclusion Criteria:

* diagnosed as epidermolysis bullosa
* not pregnant
* active disease
* more than 5 bulla-

Exclusion Criteria:

* age less than 13
* known sensitivity to tetracyclin
* abnormal liver and kidney tests.

Primary outcomes:
measure: no of blisters
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04425954: Evaluation of Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery
Official title: Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery: The Role of OCT- Angiography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pituitary Adenoma
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 14
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The participans were older than 45 years with pituitary adenoma. They did not present other ophthalmological and neurological diseases.

Brief summary: This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

Detailed description: To investigate the potential role of optical coherence tomography angiography in predicting the postoperative recovery of retinal vascular network of the optic disc in patients before and at 3 months after Endoscopic Endonasal Approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

The optical coherence tomography angiography represents a novel and non-invasive diagnostic technique that allows a detailed analysis of retinal vascular features.

Eligibility criteria: Inclusion Criteria:

* age older than 45 years
* diagnosis of pituitary adenoma
* treatment-naïve with Endoscopic Endonasal Pituitary Surgery
* absence of other neurological diseases
* absence of vitreoretinal and vascular retinal diseases

Exclusion Criteria:

* age younger than 45 years
* No diagnosis of pituitary adenoma
* previous treatments with Endoscopic Endonasal Pituitary Surgery
* presence of neurological diseases
* presence of vitreoretinal and vascular retinal diseases

Primary outcomes:
measure: Study of vessel density of the optic disc in patients underwent Endoscopic Endonasal Pituitary Surgery for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.
timeFrame: 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: University of Naples "Federico II"
Study officials:
affiliation: Federico II University
name: Gilda Cennamo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01793454: Hyperoxic Oxidative Stress During Abdominal Surgery
Official title: Comparing the Effect of Hyperoxic and Conventional Fraction of Inspired Oxygen on Oxidative Stress During Abdominal Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Response to Hyperoxia
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2013-02-15
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Our aim is to compare the effects of 80% and 40% Fraction of inspired oxygen on oxidative stress, antioxidant response (in plasma and bronchoalveolar lavage), extubation quality, preanesthetic and postanesthetic expiration tidal volumes.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing abdominal surgery, between 20-60 years old, with American Society of Anesthesiology score I or II

Exclusion Criteria:

* Patients with Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, muscle-bone diseases, inflammatory bowel diseases and patients with malnutrition.

Patients will be recruited through general surgery service of our hospital

Primary outcomes:
measure: oxidant and antioxidant response
timeFrame: 4 hours
Secondary outcomes:
measure: Hemodynamics
timeFrame: 4 hours
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Cerrahpasa Medical Faculty Anesthesiology and Reanimation Department
state: Fatih
Study officials:
affiliation: Cerrahpasa Medical Faculty Chairman of Intensive Care Department
name: Yalim Dikmen, Prof.
role: STUDY_DIRECTOR
References:
citation: Koksal GM, Sayilgan C, Aydin S, Uzun H, Oz H. The effects of sevoflurane and desflurane on lipid peroxidation during laparoscopic cholecystectomy. Eur J Anaesthesiol. 2004 Mar;21(3):217-20. doi: 10.1017/s0265021504003102.